Freestone Capital Holdings LLC Buys New Shares in Immunome, Inc. $IMNM

Key Points

• Freestone Capital Holdings LLC has purchased 61,681 shares of Immunome, Inc., valued at approximately $415,000, increasing its stake to 0.07% as of its latest SEC filing.
• JPMorgan Chase lowered its price target for Immunome from $23.00 to $22.00, while analysts generally maintain a "Moderate Buy" rating with an average target price of $23.14.
• Immunome reported a quarterly EPS of ($0.50), exceeding estimates, along with revenue of $4.02 million, which was significantly higher than analyst expectations of $1.03 million.

Freestone Capital Holdings LLC bought a new stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 61,681 shares of the company's stock, valued at approximately $415,000. Freestone Capital Holdings LLC owned approximately 0.07% of Immunome as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in shares of Immunome in the fourth quarter valued at about $70,000. Tower Research Capital LLC TRC lifted its position in shares of Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after acquiring an additional 7,129 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in shares of Immunome in the fourth quarter valued at about $95,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Immunome in the first quarter valued at about $95,000. Finally, KLP Kapitalforvaltning AS lifted its position in shares of Immunome by 140.8% in the first quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company's stock valued at $115,000 after acquiring an additional 10,000 shares in the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IMNM shares. JPMorgan Chase & Co. lowered their price objective on Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a research report on Thursday, August 7th. Wall Street Zen upgraded Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Wedbush reiterated an "outperform" rating and issued a $21.00 target price on shares of Immunome in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Immunome has an average rating of "Moderate Buy" and a consensus target price of $23.14.

Immunome Price Performance

NASDAQ IMNM opened at $10.25 on Tuesday. The stock has a market capitalization of $892.16 million, a PE ratio of -3.33 and a beta of 1.93. The business has a 50 day simple moving average of $9.65 and a two-hundred day simple moving average of $8.90. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $16.73.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.02. The firm had revenue of $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%. On average, analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Activity at Immunome

In related news, Director Jean Jacques Bienaime bought 5,000 shares of the company's stock in a transaction dated Tuesday, June 3rd. The stock was purchased at an average price of $9.38 per share, for a total transaction of $46,900.00. Following the acquisition, the director owned 36,415 shares in the company, valued at $341,572.70. This trade represents a 15.92% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 7.69% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.